TENX Earnings Date: Nov 11, 2026 (Estimated) — Tenax Therapeutics, Inc.
NASDAQ
Updated
When is TENX's next earnings date?
Tenax Therapeutics, Inc. (TENX) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.35.
How did TENX do in its last earnings report?
In its most recent report on Jul 31, 2026 (Q2 2026), Tenax Therapeutics, Inc. posted EPS of -$0.35 versus the -$0.37 estimate, a beat of 5.4%. Revenue was $0. The stock's 1-day post-earnings move was -9.3%.
How much does TENX stock move after earnings?
TENX beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.7% (up or down) in the day after earnings.
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | Q2 2026 | -0.37 | -0.35 | +5.41% | $0 | ✅ Beat | -9.27% | -11.85% | -85.89% |
| 2026-05-12 | Q1 2026 | -0.40 | -0.35 | +12.50% | $0 | ✅ Beat | +1.84% | -2.76% | -11.72% |
| 2026-03-10 | Q4 2025 | -0.75 | -0.38 | +49.33% | $0 | ✅ Beat | +31.67% | +26.86% | +36.57% |
| 2025-11-12 | Q3 2025 | -1.21 | -0.40 | +66.94% | $0 | ✅ Beat | -4.29% | +4.72% | +48.35% |
| 2025-08-13 | Q2 2025 | -0.47 | -0.27 | +42.55% | $0 | ✅ Beat | +0.68% | +1.18% | +3.38% |
| 2025-03-25 | Q4 2024 | -0.42 | -0.18 | +57.14% | $0 | ✅ Beat | +0.97% | +5.65% | -11.94% |
| 2024-11-13 | Q3 2024 | -1.39 | -0.19 | +86.33% | $0 | ✅ Beat | -3.06% | -0.82% | +20.00% |
| 2024-08-13 | Q2 2024 | -1.98 | -1.83 | +7.58% | $0 | ✅ Beat | -1.99% | +2.73% | -8.44% |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2013 · $93K total · annual
| Segment | Share | Revenue | YoY |
|---|---|---|---|
| Europe | 50.4% | $47K | — |
| United States | 49.6% | $46K | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.